Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 5988-5992

  Moret, Vincent ^a   Dereudre Bosquet, Nathalie ^b   Clayette, Pascal ^b   Laras, Younes ^a   Pietrancosta, Nicolas ^a   Rolland, Amandine ^a   Weck, Clement ^a   Marc, Sylvain ^a   Kraus, Jean Louis ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

8 Hydroxyquinoline; CCR5 receptor; CXCR4 receptor; HIV 1 Bal; HIV 1 LAV; Polyazamacrocycles

Indexed keywords

5 CHLOROMETHYL 8 HYDROXYQUINOLINE; ANTIVIRUS AGENT; CLIOQUINOL; POLYAMINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; VIRUS STRAIN;

ANTI-HIV AGENTS; HIV-1; HYDROXYQUINOLINES; MOLECULAR STRUCTURE; POLYAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750601360     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.114     Document Type: Article

References (21)

1. De Clercq E. Antiviral. Res. 67 (2005) 56
2. De Clercq E. Int. J. Biochem. Cell Biol. 36 (2004) 1800
3. Hatse S., Princen K., Gerlach L.O., Bridger G., Henson G., De Clercq E., Schwartz T.W., and Schols D. Mol. Pharmacol. 60 (2001) 164
4. Hatse S., Princen K., De Clercq E., Rosenkilde M.M., Schwartz T.W., Hernandez-Abad P.E., Skerlj R.T., Bridger G.J., and Schols D. Biochem. Pharmacol. 70 (2005) 752
5. Gerlach L.O., Skerlj R.T., Bridger G.J., and Schwartz T.W. J. Biol. Chem. 276 (2001) 14153
6. Inouye Y., Kanamori T., Sugiyama M., Yoshida T., Koike T., Shionoya M., Enomoto K., Suehiro K., and Kimura E. Antiviral Chem. Chemother. 6 (1995) 337
7. Hunter T.M., McNae I.W., Liang X., Bella J., Parsons S., Walkinshaw M.D., and Sadler P.J. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2288
8. Princen K., Hatse S., Vermeire K., Aquaro S., De Clercq E., Gerlach L.O., Rosenkilde M., Schwartz T.W., Skerlj R., Bridger G., and Schols D. J. Virol. 78 (2004) 12996
9. Barnham K.J., Masters C.L., and Bush A.I. Nat. Rev. Drug Discov. 3 (2004) 205
10. Di Vaira M., Bazzicalupi C., Orioli P., Messori L., Bruni B., and Zatta P. Inorg. Chem. 43 (2004) 3795
11. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., and Fridkin M. Bioorg. Med. Chem. 13 (2005) 773
12. Boitrel B., Andrioletti B., Lachkar M., and Guilard R. Tetrahedron Lett. 36 (1995) 4995
13. Dessolin J., Galea P., Vlieghe P., Chermann J.C., and Kraus J.L. J. Med. Chem. 42 (1999) 229
14. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., and Montagnier L. Science 220 (1983) 868
15. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., and De Clercq E. J. Virol. Methods 20 (1988) 309
16. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., and Popovic M. Science 233 (1986) 215
17. De Clercq E. Nat. Rev. Drug Discov. 2 (2003) 581
18. Mosoian, A.; Klotman, M.E. In 5th conference on retroviruses and opportunistic infections February 1-5, 1998.
19. Princen K., and Schols D. Cytokine Growth Factor Rev. 16 (2005) 659
20. Nottet H.S., Flanagan E.M., Flanagan C.R., Gelbard H.A., Gendelman H.E., and Reinhard Jr. J.F. J. Neurovirol. 2 (1996) 111
21. Sei S., Saito K., Stewart S.K., Crowley J.S., Brouwers P., Kleiner D.E., Katz D.A., Pizzo P.A., and Heyes M.P. J. Infect. Dis. 172 (1995) 638